Filing Details
- Accession Number:
- 0001415889-25-011992
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-05 16:54:51
- Reporting Period:
- 2025-05-01
- Filing Date:
- 2025-05-05
- Accepted Time:
- 2025-05-05 16:54:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1730430 | Kiniksa Pharmaceuticals International Plc | KNSA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1857177 | Ross Moat | 23 Old Bond Street, Third Floor London X0 W1S 4PZ | Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Share | Acquisiton | 2025-05-02 | 3,850 | $17.76 | 13,265 | No | 4 | M | Direct | |
| Class A Ordinary Share | Disposition | 2025-05-02 | 3,850 | $28.00 | 9,415 | No | 4 | S | Direct | |
| Class A Ordinary Share | Acquisiton | 2025-05-05 | 6,272 | $17.76 | 15,687 | No | 4 | M | Direct | |
| Class A Ordinary Share | Disposition | 2025-05-05 | 6,272 | $28.00 | 9,415 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Ordinary Share | Performance Share Unit | Acquisiton | 2025-05-01 | 4,976 | $0.00 | 4,976 | $0.00 |
| Class A Ordinary Share | Performance Share Unit | Acquisiton | 2025-05-01 | 5,225 | $0.00 | 5,225 | $0.00 |
| Class A Ordinary Share | Performance Share Option | Acquisiton | 2025-05-01 | 8,043 | $0.00 | 8,043 | $27.74 |
| Class A Ordinary Share | Performance Share Option | Acquisiton | 2025-05-01 | 8,303 | $0.00 | 8,303 | $27.74 |
| Class A Ordinary Share | Share Option | Disposition | 2025-05-02 | 3,850 | $0.00 | 3,850 | $17.76 |
| Class A Ordinary Share | Share Option | Disposition | 2025-05-05 | 6,272 | $0.00 | 6,272 | $17.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,976 | No | 4 | A | Direct | ||
| 5,225 | No | 4 | A | Direct | ||
| 8,043 | 2035-04-30 | No | 4 | A | Direct | |
| 8,303 | 2035-04-30 | No | 4 | A | Direct | |
| 33,661 | 2033-08-31 | No | 4 | M | Direct | |
| 27,389 | 2033-08-31 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
- The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
- The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
- The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
- The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
Billionaire Hedge Funds
